# Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

> **NCT00364364** · EARLY_PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Radiolabeled humanized PAM4 IgG

## Key facts

- **NCT ID:** NCT00364364
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2019-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364364, "Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00364364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*